PharmacyCodes



Repaglinidum [Inn-Latin] en es it fr

Categorie

Repaglinidum [Inn-Latin] Les marques, Repaglinidum [Inn-Latin] Analogs

Repaglinidum [Inn-Latin] Les marques melange

  • No information avaliable

    • Repaglinidum [Inn-Latin] Formule chimique

    C27H36N2O4

    Repaglinidum [Inn-Latin] RX lien

    http://www.rxlist.com/cgi/generic/prandin.htm

    Repaglinidum [Inn-Latin] FDA fiche

    Repaglinidum_[Inn-Latin] FDA

    Repaglinidum [Inn-Latin] msds (fiche de securite des materiaux)

    Repaglinidum_[Inn-Latin] MSDS

    Repaglinidum [Inn-Latin] Synthese de reference

    W. Grell et al. Int PCT. pat. Appl. WO 93 00 337

    Repaglinidum [Inn-Latin] Poids moleculaire

    452.586 g/mol

    Repaglinidum [Inn-Latin] Point de fusion

    130-131 oC

    Repaglinidum [Inn-Latin] H2O Solubilite

    Aucune information disponible

    Repaglinidum [Inn-Latin] Etat

    Solid

    Repaglinidum [Inn-Latin] LogP

    5.798

    Repaglinidum [Inn-Latin] Formes pharmaceutiques

    Tablet

    Repaglinidum [Inn-Latin] Indication

    Pour le traitement du diabète de type II.

    Repaglinidum [Inn-Latin] Pharmacologie

    Le répaglinide est un sang hypoglycémiants oraux médicaments de la classe méglitinide utilisés dans la gestion du diabète de type 2 (aussi appelé diabète non insulino-dépendants sucré ou DNID). Le répaglinide abaisse la glycémie en stimulant la libération d'insuline par le pancréas. Cette action dépend de fonctionnement des cellules bêta des îlots pancréatiques. Libération d'insuline glucose-dépendante est et diminue à des concentrations de glucose faible.

    Repaglinidum [Inn-Latin] Absorption

    Rapide (biodisponibilité est de 56%)

    Repaglinidum [Inn-Latin] Toxicite

    DL50> 1 g / kg (rat) (W. Grell)

    Repaglinidum [Inn-Latin] Information pour les patients

    PATIENT INFORMATION

    Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

    Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.

    Repaglinidum [Inn-Latin] Organismes affectes

    Les humains et autres mammifères